Allergy Therapeutics Cash Flow-to-Debt Ratio
Allergy Therapeutics cash flow-to-debt ratio. Allergy Therapeutics (AGY) has a Cash Flow-to-Debt Ratio of -0.18x as of December 2025, meaning its operating cash flow of GBX-11.71 Million could theoretically repay 0% of its total liabilities (GBX66.75 Million) in one year. Check Allergy Therapeutics earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Allergy Therapeutics (2002–2025)
Cash flow-to-debt ratio of Allergy Therapeutics from 2002 to 2025. Historical debt coverage capacity for Allergy Therapeutics across 24 annual periods. Check AGY capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Allergy Therapeutics Cash Flow-to-Debt Ratio by Year (2002–2025)
Allergy Therapeutics cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Allergy Therapeutics. For the full cash flow conversion analysis, see Allergy Therapeutics (AGY) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.30x | GBX-28.72 Million | GBX95.74 Million | ▲ +43.0% |
| 2024 | -0.53x | GBX-32.14 Million | GBX61.12 Million | ▼ -10.1% |
| 2023 | -0.48x | GBX-30.92 Million | GBX64.70 Million | ▼ -19.1% |
| 2022 | -0.40x | GBX-14.11 Million | GBX35.18 Million | ▼ -286.3% |
| 2021 | 0.22x | GBX8.52 Million | GBX39.55 Million | ▼ -25.6% |
| 2020 | 0.29x | GBX12.28 Million | GBX42.44 Million | ▲ +59.8% |
| 2019 | 0.18x | GBX5.60 Million | GBX30.94 Million | ▲ +233.2% |
| 2018 | -0.14x | GBX-3.80 Million | GBX27.98 Million | ▼ -2177.6% |
| 2017 | 0.01x | GBX178.00K | GBX27.22 Million | ▲ +101.5% |
| 2016 | -0.45x | GBX-11.84 Million | GBX26.36 Million | ▼ -333.5% |
| 2015 | 0.19x | GBX3.12 Million | GBX16.23 Million | ▲ +18.0% |
| 2014 | 0.16x | GBX2.17 Million | GBX13.32 Million | ▼ -4.1% |
| 2013 | 0.17x | GBX2.43 Million | GBX14.29 Million | ▼ -22.2% |
| 2012 | 0.22x | GBX2.88 Million | GBX13.16 Million | ▲ +407.5% |
| 2011 | -0.07x | GBX-2.03 Million | GBX28.48 Million | ▼ -205.5% |
| 2010 | 0.07x | GBX1.70 Million | GBX25.23 Million | ▲ +793.8% |
| 2009 | -0.01x | GBX-440.00K | GBX45.25 Million | ▲ +98.3% |
| 2008 | -0.56x | GBX-19.32 Million | GBX34.47 Million | ▲ +54.3% |
| 2007 | -1.23x | GBX-18.88 Million | GBX15.40 Million | ▲ +21.7% |
| 2006 | -1.56x | GBX-8.10 Million | GBX5.18 Million | ▼ -17953.9% |
| 2005 | -0.01x | GBX-57.00K | GBX6.58 Million | ▼ -101.9% |
| 2004 | 0.46x | GBX1.91 Million | GBX4.16 Million | ▲ +22.6% |
| 2003 | 0.37x | GBX2.10 Million | GBX5.60 Million | ▲ +362.1% |
| 2002 | -0.14x | GBX-2.01 Million | GBX14.07 Million | — |